Featured Company News – Portola Pharmaceuticals’ AndexXa(R) Biologics License Application Resubmission Accepted for Review by US FDA

Research Desk Line-up: Alnylam Pharma Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) (“Portola”), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=PTLA. The Company announced on August 15, 2017, that the US Food and Drug Administration (FDA) have found its resubmitted Biologics License Application (BLA) for AndexXa® (andexanet alfa) to be acceptable for review, with an action due date of February 02, 2018. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) for due-diligence and potential coverage as the Company reported on August 09, 2017, its consolidated financial results for Q2 2017, and also highlighted recent progress in advancing its pipeline. Tune in to our site to register for a free membership, and be among the early birds that get our report on Alnylam Pharma when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on PTLA; also brushing on ALNY. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=PTLA

http://protraderdaily.com/optin/?symbol=ALNY

The License Application Resubmission

Portola resubmitted its BLA to the Center for Biologics Evaluation and Research (CBER) of the US FDA for AndexXa® on August 03, 2017. The resubmission primarily comprises supplemental information related to analytics and manufacturing. This is in sync with what FDA requested in a complete response letter issued to Portola in August 2016.

AndexXa® Designed to Treat Uncontrolled Bleeding

Portola has developed AndexXa® as a universal reversal agent for patients who have been anticoagulated with an oral or injectable Factor Xa inhibitor and experienced a serious uncontrolled or life-threatening bleeding event, or those who require urgent or emergency surgery. The above mentioned BLA basically seeks initial approval of AndexXa® for reversal of the anticoagulant effects of apixaban and rivaroxaban in patients experiencing uncontrolled or life-threatening bleeding.

How AndexXa® Works

AndexXa® (i.e. andexanet alfa) is an investigational drug. It is basically a modified human Factor Xa molecule which acts as a decoy to target and sequester, with high specificity, both oral and injectable Factor Xa inhibitors in the blood. Once the Factor Xa inhibitors are bound, they are unable to bind to and inhibit native Factor Xa. This allows for the restoration of normal hemostatic processes. In fact, AndexXa® is the first compound that is being studied as an antidote for Factor Xa inhibitors that directly and specifically reverse the anti-Factor Xa activity, the anticoagulant mechanism of these agents.

Can Benefit Around 150,000 US Patients

AndexXa® is expected to benefit a vast number of patients in the United States. In 2016, around 90,000 patients in the US treated with oral Factor Xa inhibitors were admitted to the hospital due to subsequent bleeding. It is projected that approximately 150,000 US patients could benefit from an antidote annually, including the patients who are taking the injectable Factor Xa inhibitor enoxaparin. As of now, there are no approved Factor Xa inhibitor antidotes.

Portola Reports Q2 2017 Financial Results

On August 10, 2017, Portola reported financial results and shared a corporate update for the quarter ended June 30, 2017. The Company achieved total revenue of $3.8 million for Q2 2017 compared to $4.2 million for Q2 2016. The Company reported a net loss of $69.7 million in Q2 2017 compared to a net loss of $57.3 million for the same period in 2016. Thus, the net loss per share increased from $1.02 to $1.22.

An important development in the second quarter was the FDA approval for their first product, Bevyxxa®, in June 2017. Bevyxxa® is an oral, once-daily Factor Xa inhibitor.

Last Close Stock Review

Portola Pharma’s share price finished yesterday’s trading session at $54.70, marginally down 0.56%. A total volume of 650.67 thousand shares have exchanged hands. The Company’s stock price soared 38.80% in the last three months, 77.83% in the past six months, and 105.56% in the previous twelve months. Additionally, the stock skyrocketed 143.76% since the start of the year. The stock currently has a market cap of $3.14 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 472897